Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis
NCT01074346 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2014-02-19
Summary
This is an observational study to assess the tolerability of Rebif treatment in Korean multiple sclerosis (MS) subjects.
Conditions
Interventions
- DRUG
-
Interferon-β-1a
Interferon-β-1a according to the standard practice
Sponsors & Collaborators
-
Merck KGaA, Darmstadt, Germany
lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-08-31
- Primary Completion
- 2011-11-30
- Completion
- 2011-11-30
Countries
- South Korea
Study Locations
More Related Trials
-
An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters
NCT01112345 ·Status: COMPLETED
-
A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis
NCT00441103 ·Status: COMPLETED ·Phase: PHASE3
-
Transition to Rebif New Formulation
NCT00619307 ·Status: COMPLETED ·Phase: PHASE3
-
A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)
NCT01142492 ·Status: COMPLETED
-
A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
NCT01142466 ·Status: COMPLETED ·Phase: PHASE4
-
Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis
NCT00367484 ·Status: COMPLETED ·Phase: PHASE4
-
Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®
NCT01075880 ·Status: COMPLETED
-
An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy
NCT01141751 ·Status: COMPLETED
-
A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly
NCT01198132 ·Status: COMPLETED ·Phase: PHASE2
-
An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone
NCT01142518 ·Status: COMPLETED
-
REbif FLEXible Dosing in Early Multiple Sclerosis (MS)
NCT00404352 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
NCT00050778 ·Status: COMPLETED ·Phase: PHASE2
-
An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)
NCT01110993 ·Status: COMPLETED
-
Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis
NCT00110396 ·Status: COMPLETED ·Phase: PHASE3
-
Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]
NCT01134627 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
NCT01412333 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
NCT01247324 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)
NCT00914758 ·Status: UNKNOWN
-
Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)
NCT00813709 ·Status: COMPLETED ·Phase: PHASE3
-
Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)
NCT02921035 ·Status: COMPLETED
-
MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)
NCT02949908 ·Status: TERMINATED
-
Therapy Optimization in Multiple Sclerosis (MS)
NCT00819000 ·Status: COMPLETED
-
Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™
NCT02254304 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients
NCT01201343 ·Status: COMPLETED ·Phase: PHASE4
-
A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome
NCT00287079 ·Status: COMPLETED ·Phase: PHASE3